HDL Announces Acquisition of Harris Scientific

By LabMedica International staff writers
Posted on 31 May 2011

Health Diagnostic Laboratory Inc. (HDL, Inc.; Richmond, VA, USA), a College of American Pathologists (CAP) accredited laboratory specializing in health management, announced that it will expand its comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases through the acquisition of Harris Scientific, Inc., a company providing omega-3 fatty acid testing.

Dr. William Harris (of Harris Scientific) will join HDL to expand his work in fatty acid analysis, and to enhance HDL's fatty acid panel of tests. This panel includes measurement of the level of omega-3, omega-6, cis-monounsaturated, saturated and transfatty acids in erythrocyte membranes.

By reducing inflammation, blood clotting, and improving membrane function, omega-3's can reduce risk of heart disease–including fatal heart attacks and heart failure–both in persons with a history of cardiovascular disease and in healthy individuals.

Tonya Malory, CEO and cofounder of HDL commented, "With Dr. Harris joining HDL, the company will be positioned to establish the Fatty Acid profile as the worldwide standard for tracking and optimizing omega-3 status which will result in reduced morbidity and mortality from today's chronic diseases."

Related Links:
Health Diagnostic Laboratory Inc.